

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 6185)**

**INSIDE INFORMATION**

**RESULTS FORECAST FOR THE YEAR 2022**

This announcement is made by CanSino Biologics Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

**I. Results Forecast**

**A. Period of the results forecast**

The period of the results forecast is from January 1, 2022 to December 31, 2022 (the “**Reporting Period**”).

**B. Details of the results forecast**

1. According to the preliminary estimation of the Company, the net loss attributable to the shareholders of the Company for the year ended December 31, 2022 is expected to be RMB830.0 million to RMB996.0 million.
2. The net loss attributable to the shareholders of the Company after deducting the non-recurring profit or loss for the year ended December 31, 2022 is expected to be RMB945.0 million to RMB1,134.0 million.

**C. Preliminary audit of the results forecast**

This results forecast has not been audited or reviewed by independent auditors.

## II. Performance in the corresponding period in the last year

During the corresponding period in 2021, the net profit attributable to the shareholders of the Company was approximately RMB1,914.4 million; the net profit attributable to the shareholders of the Company after deducting non-recurring profit or loss was approximately RMB1,797.0 million.

## III. Reasons for changes in results

During the Reporting Period, the domestic and overseas market environment of COVID-19 vaccines has changed significantly. The demand for COVID-19 vaccines has decreased significantly compared with the corresponding period last year. The growth rate of COVID-19 vaccination worldwide has decelerated, and the supply of COVID-19 vaccines exceeds the demand in some regions. With the intensified competition of market, the Company's sales revenue of COVID-19 vaccine products decreased significantly compared with the corresponding period last year. Meanwhile, the sales expenses increased compared with the corresponding period last year due to the continuous promotion of commercialization, and the Group recognized the provision of COVID-19 vaccine products related inventory with signs of impairment. As a result, the Company incurred a loss in the net profit attributable to the shareholders of the Company.

## IV. Risk Factors

The Company does not have any significant uncertainty factors that may affect the accuracy of the results forecast.

## V. Other Information

The results forecast above is only a preliminary calculation performed by the Company and the specific and accurate financial data shall be subject to the audited annual report of 2022 officially disclosed by the Company. Investors are reminded to exercise caution when making investment decisions.

By order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, January 30, 2023

*As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.*